Articles On Dimerix (ASX:DXB)

Special Report: Melbourne biotech company Dimerix (ASX:DXB) is working with independent researchers to ship its lead drug candidate DMX-200 to ... Read More The post Global study will test Dimerix drug compound DMX-200 as COVID-19 treatment...

Special Report: Dimerix is developing a potential treatment for constructive obstructive pulmonary disease (COPD), the fourth-leading cause of death worldwide. ... Read More The post Dimerix’s DMX-700 drug candidate has enormous potential a...

Melbourne biotech release analysis of study that sent share price crashing last month Study showed drug candidate did seem to ... Read More The post Dimerix shares up after analysis on DMX-200 diabetic kidney disease trial results appeared...

Dimerix (ASX:DXB) says it has navigated another important step in the development of its lead compound DMX-200 for the treatment of kidney disease.

Shares of Melbourne-based biotechnology company Dimerix Ltd [ASX:DXB] have gained 9% today, to trade at 32 cents at the time of writing. The DXB share price rose on the back of encouraging results that will support... The post Dimerix Share...

Here’s our fortnightly wrap of all the news driving ASX health stocks. The health sector made a bit of progress over the last fortnight, with 64 small-cap life sciences gaining ground and just 52 losing it. Another 15 companies were flat....

Melbourne-based clinical-stage biopharmaceutical company Dimerix (ASX:DSB) has updated on clinical trials of its drug candidate DMX-200 for kidney diseases.

Summary ASX listed clinical-stage healthcare company Dimerix Limited announced positive results in Phase 2 clinical trial of DMX-200 in diabetic kidney disease patients. Following the announcement, Dimerix Limited’s share price fell sha...

A quick wrap of the ASX’s key winners and losers on Monday, September 14. Data is taken after the market closes at 4pm AEST. Stocks highlighted in yellow made potentially market-moving announcements during the day.   WINNERS Code Na...

Special Report: Dimerix plans to further explore the potential of DMX-200 to treat kidney diseases following the completion of a positive and informative phase-2 trial. Dimerix (ASX:DXB) says it will progress with research on its chemokine...

The Dimerix Ltd (ASX: DXB) share price has plummeted 63.51% today to 27 cents. This came after the drug company reported the results of its phase 2 study of DMX-200 in patients with diabetic kidney disease. Why has the Dimerex share price...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays. Themes of the week We’re coming...

Melbourne-based biotech company Dimerix Ltd [ASX:DXB] got a shot in the arm recently after being awarded $1 million from the Australian government’s Medical Research Future Fund. This has pushed the DXB share price up 7.14% to trade at 75 c...

Right now investors have a range of areas to choose great ASX shares for growth. On one hand we see radical changes in short term credit with the buy now, pay later companies led by Afterpay Ltd (ASX: APT). On the other hand, changes in th...

By Tim Boreham, Editor, The New Criterion The ASX biotechs surfing the COVID-19 story Normally investors shun speculative plays in times of market uncertainties, but that’s not been the case with ASX-listed life sciences stocks across the d...

Normally investors shun speculative plays in times of market uncertainties, but that’s not been the case with ASX-listed life science stocks across the drug, diagnostics and device sectors. Naturally, the biotechs drawing a connection with...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week With quart...

Summary Mesoblast disclosed that the Phase 3 clinical trial of Remestemcel-L is anticipated to complete recruitment in September 2020 in the US. At the end of the quarter ended June 2020, Mesoblast had nearly US$129.3 million cash on ha...

Melbourne-based biopharmaceutical company Dimerix (ASX:DXB) has reported positive results from the clinical trial of its drug candidate DMX-200.

A quick wrap of the ASX’s key winners and losers on Wednesday, July 29. Data is taken after the market closes at 4pm EST. Stocks highlighted in yellow made market-moving announcements during the day. Today 529 stocks rose, 801 declined and...

Drug development company Dimerix (ASX: DXB) emerged from a trading halt today with top-line results from its phase 2a ACTION study into DMX-200 for treatment of focal segmental glomerulosclerosis (FSGS), a rare kidney disorder that often le...

Dimerix’s (ASX: DXB) phase-two trial for focal segmental glomerulosclerosis (FSGS) has met both primary and secondary endpoints, with 86 per cent of patients showing a response to the drug DMX-200 versus placebo. This morning’s news drove t...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Special Report: With results from the first of three clinical trials set to come in this year, shareholders are asking: is it smart for Dimerix to licence its drug candidates for the final stages, or go it alone?   As biotech Dimerix (ASX:D...

Special Report: With results from the first of three clinical trials set to come in this year, shareholders are asking: is it smart for Dimerix to licence its drug candidates for the final stages, or go it alone?   As biotech Dimerix (ASX:D...

In June, ASX-listed companies of all sizes continued to raise capital but the small-cap sector was particularly busy. Stocks with market capitalisations of under $100m at the time of the deal raised $274m in the last month. This is triple M...

Stockhead’s resident Health and Biotech expert Tim Boreham is putting down the pen and picking up the microphone for another instalment of The Health Kick Podcast. In this episode Tim catches up with CEO and MD of Dimerix, Nina Webster. Dim...

Clinical-stage biopharmaceutical company Dimerix (ASX:DXB) has announced the placement of 16,222,580 fully paid ordinary shares to institutional and sophisticated investors at a price of $0.36 per share to raise $5.8 million before...

Special Report: Biotech Dimerix wins over institutional investors as it prepares for a global Phase 3 COVID-19 trial. Hotshot biotech Dimerix (ASX:DXB) is finally on the radar of institutional investors, who bought in for the first time via...

On Stockhead today, how a ‘tired’ gold mine transformed shell company Bellevue into a $650m market darling, cobalt has stumbled this year but EV growth is expected to drive demand and prices and is this a new dawn for nickel? But first…   T...

Drug discovery tearaway Dimerix – which is trading up more than 200 per cent in the past six months – is making a trip to equity capital markets. 

Special Report: Dimerix expects results for its FSGS clinical trial in July and says so far, it’s meeting the primary endpoint.    Biotech Dimerix has dosed its last patient in a crucial phase 2a clinical trial on focal segmental glomerulos...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week The market...

Here’s our fortnightly wrap of all the news driving ASX health stocks. Of the ASX’s 134-odd small cap health stocks and of those which were trading on Wednesday, 71 were in positive territory over the last fortnight, 11 were flat and 52 saw...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week As markets...

A quick wrap of the key winners and losers on Thursday, June 4. Data is taken after the market closes at 4pm EST. Stocks highlighted in yellow made potentially market-moving announcements during the day.   Code Name Price % Chg...

A lead drug candidate developed by clinical-stage biopharmaceutical company Dimerix Limited (ASX: DXB) has been selected for inclusion in a global study aimed at treating patients with acute respiratory distress syndrome as a result of COVI...

The Dimerix Ltd (ASX: DXB) share price has raced out of the gates this morning following news that one of its treatments has been included in a global COVID-19 clinical study. Dimerix is a clinical-stage biopharmaceutical company that deve...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Special Report: Dimerix’s key drug has been selected for a global trial looking at COVID-19 treatments. Biotech Dimerix’s (ASX: DXB) key drug candidate will be used in a global program aimed at treating patients who have Acute Respiratory...

Dimerix (ASX:DXB) has announced that its DMX-200 has been selected for inclusion in the protocol as a new treatment arm in a clinical trial for Acute Respiratory Distress Syndrome as a result of COVID-19.

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week Markets be...

Special Report: Drug developer Dimerix hasn’t been affected by the March market rout and since April has surged. What is behind this push? Shares in drug developer Dimerix (ASX:DXB) have doubled in value in the last six months and the stock...

Neuren Pharmaceuticals (ASX: NEU) is getting interesting results from a mouse trial of a treatment for Phelan-McDermid syndrome (PMS), a rare genetic illness which exhibits symptoms of conditions including autism and epilepsy. The study fou...

Clinical-stage biopharmaceutical company Dimerix (ASX: DXB) received an operational boost earlier today after announcing that patients from phase 2 trials will continue treatment with its DMX-200 adjunct therapy under Australia’s Therapeuti...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Here’s our fortnightly wrap of all the news driving ASX health stocks. Of the ASX’s 136-odd small cap health stocks, 47 saw their share prices fall, 67 improved and 22 were flat. >> Scroll down for a table showing the performance of s...

Biopharmaceutical company Dimerix (DXB) has announced the outcomes for its phase 2 clinical trials in treating patients with its DMX-200 receptor blocker The Committee did not find any safety concerns in patients administered with DMX-200...

You don’t need a PhD to run a biotech, but sometimes it helps, as these companies deal in one of the most complicated mysteries still to be solved today: the human body. Biotech CEOs and chairs tend to be the cross-over scientists. However,...